These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 28968445)

  • 1. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
    Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
    Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
    Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
    Canessa PA; Ferro P; Manta C; Sivori M; Franceschini MC; Fedeli F; Roncella S
    Med Oncol; 2013; 30(3):649. PubMed ID: 23873013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
    Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
    Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
    Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
    Inoue C; Kato S; Higuchi K; Inoue H
    Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):243-7. PubMed ID: 17419436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
    Kim YK; Kim JS; Lee KW; Yi CA; Goo JM; Jung SH
    Korean J Radiol; 2016; 17(4):545-53. PubMed ID: 27390546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
    Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
    Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokeratin markers in malignant pleural mesothelioma.
    Nisman B; Barak V; Heching N; Kramer M; Reinus C; Lafair J
    Cancer Detect Prev; 1998; 22(5):416-21. PubMed ID: 9727622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.